RT: For Decision Makers in Respiratory Care
  • Disorders & Diseases
    • Chronic Pulmonary Disorders
    • Infectious Diseases
    • Critical Care
    • Cardiopulmonary & Thoracic
    • Sleep Medicine
  • Public Health
    • Smoking
    • Healthcare & Policy
    • Pediatrics
  • Products & Treatment
    • Monitoring & Treatment
    • Diagnostics & Testing
    • Pharmaceuticals
    • Industry & Regulatory News
  • Department Management
    • Clinical
    • Education
    • Conferences & CEU
  • Edition Archive

Select Page

Tag: dupilumab Dupixent

All

Latest
Dupilumab Lessens Disease in COPD Patients

Dupilumab Lessens Disease in COPD Patients

The monoclonal antibody is the first biologic shown to improve clinical outcomes in COPD, according to investigators.

  • NIH to Trial Dupilumab for Asthma

  • NIH Launches Monoclonal Antibody Trial to Treat Asthma in Urban Youth

  • Functional Respiratory Imaging to Assess Dupilumab

  • Dupilumab Gets Expanded Approval for Moderate-to-severe Asthma in Children Age 6-11

  • Dupilumab May Improve Lung Function in Children Age 6-11 with Uncontrolled, Moderate to Severe Asthma

  • Dupilumab Significantly Reduced Asthma Exacerbations in Children Ages 6-11

  • FDA to Review Expanded Application of Dupixent for Childhood Asthma

All

Latest
Self-administered Dupixent Pen Approved for Asthma, CRSwNP

Self-administered Dupixent Pen Approved for Asthma, CRSwNP

FDA approved a 300 mg single-dose pre-filled pen for Dupixent (dupilumab) to treat atopic dermatitis, asthma and chronic rhinosinusitis with nasal polyposis (CRSwNP).

  • Dupixent Effective for Chronic Rhinosinusitus with Nasal Polyps

    Dupixent Effective for Chronic Rhinosinusitus with Nasal Polyps

  • Dupilumab Improves QoL in Uncontrolled Asthma and Allergic Rhinitis

    Dupilumab Improves QoL in Uncontrolled Asthma and Allergic Rhinitis

All

Latest
Sorry, No Posts Found
Sorry, No Posts Found

Resources

  • Edition Archive
  • Featured Reports
  • Podcasts
  • White Papers
  • Webinars
  • Videos

Helpful Links

  • Marketing Solutions
  • Subscribe
  • Contact Us

Designed by Elegant Themes | Powered by WordPress

  • Privacy Policy
  • Terms of Service
  • Copyright